Cargando…

Increased STAT1 Signaling in Endocrine-Resistant Breast Cancer

Proteomic profiling of the estrogen/tamoxifen-sensitive MCF-7 cell line and its partially sensitive (MCF-7/LCC1) and fully resistant (MCF-7/LCC9) variants was performed to identify modifiers of endocrine sensitivity in breast cancer. Analysis of the expression of 120 paired phosphorylated and non-ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Rui, Faratian, Dana, Sims, Andrew H., Wilson, Danielle, Thomas, Jeremy S., Harrison, David J., Langdon, Simon P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984130/ https://www.ncbi.nlm.nih.gov/pubmed/24728078 http://dx.doi.org/10.1371/journal.pone.0094226

Ejemplares similares

GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines
por: Morgan, Kevin, et al.
Publicado: (2011)

Sprouty 2 Is an Independent Prognostic Factor in Breast Cancer and May Be Useful in Stratifying Patients for Trastuzumab Therapy
por: Faratian, Dana, et al.
Publicado: (2011)

Predictive markers of endocrine response in breast cancer
por: Mosly, Duniya, et al.
Publicado: (2018)

Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation
por: Meyer, Colette, et al.
Publicado: (2013)

The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer
por: Huang, Rui, et al.
Publicado: (2015)

Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer
por: Taylor, Karen J, et al.
Publicado: (2010)

Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosis
por: Verleyen, Wim, et al.
Publicado: (2015)

Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network
por: Lebedeva, Galina, et al.
Publicado: (2012)

Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers
por: Briffa, Romina, et al.
Publicado: (2015)

Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer
por: Simões, Bruno M., et al.
Publicado: (2020)

Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance
por: Palmieri, C, et al.
Publicado: (2013)

A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk
por: Katz, E, et al.
Publicado: (2010)

Notch Signaling Pathway and Endocrine Resistance in Breast Cancer
por: Bai, Jing-Wen, et al.
Publicado: (2020)

Systems pathology
por: Faratian, Dana
Publicado: (2010)

A Role for Notch Signalling in Breast Cancer and Endocrine Resistance
por: Acar, Ahmet, et al.
Publicado: (2016)

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
por: Sims, A H, et al.
Publicado: (2012)

Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers
por: Clarke, Robert, et al.
Publicado: (2015)

Diversity of Matriptase Expression Level and Function in Breast Cancer
por: Welman, Arkadiusz, et al.
Publicado: (2012)

HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer
por: Jarman, Edward J., et al.
Publicado: (2019)

Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers
por: Selli, Cigdem, et al.
Publicado: (2016)

Statins and endocrine resistance in breast cancer
por: Hyder, Tara, et al.
Publicado: (2021)

Specification of the endocrine primordia controlling insect moulting and metamorphosis by the JAK/STAT signalling pathway
por: García-Ferrés, Mar, et al.
Publicado: (2022)

C35 overexpression defines subsets of human breast cancer and its immunoreceptor tyrosine-based activation motif represents a novel treatment target
por: Katz, E, et al.
Publicado: (2008)

Pathways to Endocrine Therapy Resistance in Breast Cancer
por: Haque, Md. Moquitul, et al.
Publicado: (2019)

Endocrine resistant breast cancer: brain metastasis
por: Willman, Matthew, et al.
Publicado: (2022)

Evaluation of Gene Expression Data From Cybrids and Tumours Highlights Elevated NDRG1-Driven Proliferation in Triple-Negative Breast Cancer
por: Mishra, Akanksha, et al.
Publicado: (2020)

Non-canonical Estrogen Signaling in Endocrine Resistance
por: Ranganathan, Prathibha, et al.
Publicado: (2019)

Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development
por: Madden, Stephen F., et al.
Publicado: (2022)

Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance
por: García-Becerra, Rocío, et al.
Publicado: (2012)

Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer
por: Chu, Xiao, et al.
Publicado: (2019)

SAT-119 Targeting Glutamate Metabolism and Signaling in ER+, Endocrine Therapy-Resistant Breast Cancer
por: Olukoya, Ayodeji O, et al.
Publicado: (2020)

Cannibalism, cell survival, and endocrine resistance in breast cancer
por: Clarke, Robert
Publicado: (2011)

Predicting response/resistance to endocrine therapy for breast cancer
por: Miller, WR, et al.
Publicado: (2005)

New insights into acquired endocrine resistance of breast cancer
por: Fan, Ping, et al.
Publicado: (2019)

Exploring new pathways in endocrine-resistant breast cancer
por: de Pinho, Inês Soares, et al.
Publicado: (2022)

Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
por: Bonello, Maria, et al.
Publicado: (2018)

Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model
por: Moore, Kate M., et al.
Publicado: (2022)

JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
por: Stevens, Laura E., et al.
Publicado: (2023)

Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment
por: Li, Yuan, et al.
Publicado: (2021)

VAV3 mediates resistance to breast cancer endocrine therapy
por: Aguilar, Helena, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2l05h1i93krlevqug35mda05k7